These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18715730)

  • 1. [Yellow fever vaccination in non-immunocompetent patients].
    Bruyand M; Receveur MC; Pistone T; Verdière CH; Thiebaut R; Malvy D
    Med Mal Infect; 2008 Oct; 38(10):524-32. PubMed ID: 18715730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review.
    Martin C; Domingo C; Bottieau E; Buonfrate D; De Wit S; Van Laethem Y; Dauby N
    Clin Microbiol Infect; 2021 Jul; 27(7):958-967. PubMed ID: 33813107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients.
    Wieten RW; Goorhuis A; Jonker EFF; de Bree GJ; de Visser AW; van Genderen PJJ; Remmerswaal EBM; Ten Berge IJM; Visser LG; Grobusch MP; van Leeuwen EMM
    J Infect; 2016 Jun; 72(6):713-722. PubMed ID: 27017899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccination status and safety in hemodialysis patients.
    Facincani T; Guimarães MN; De Sousa Dos Santos S
    Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
    Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
    Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of the yellow Fever vaccine: a retrospective study.
    Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
    J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccination and pregnancy: a four-year prospective study.
    Nasidi A; Monath TP; Vandenberg J; Tomori O; Calisher CH; Hurtgen X; Munube GR; Sorungbe AO; Okafor GC; Wali S
    Trans R Soc Trop Med Hyg; 1993; 87(3):337-9. PubMed ID: 8236412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal myelitis associated with yellow fever vaccination.
    Chaves M; Riccio P; Patrucco L; Rojas JI; Cristiano E
    J Neurovirol; 2009 Jul; 15(4):348-50. PubMed ID: 19579072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
    Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
    Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
    Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
    Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of Yellow Fever vaccine-induced antibodies after cord blood stem cell transplant.
    Avelino-Silva VI; Freire Mda S; Rocha V; Rodrigues CA; Novis YS; Sabino EC; Kallas EG
    Hum Vaccin Immunother; 2016 Apr; 12(4):937-8. PubMed ID: 26618995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suspected YF-AND after yellow fever vaccination in Finland.
    Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
    J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.